Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs TJX Companies Inc (TJX) Price & Performance

ADMA Biologics IncTrade
TJX Companies IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs TJX Companies Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while TJX Companies Inc trades at $152.9 (market cap $172.05B). The key difference: TJX Companies Inc is far larger — about 77.5× ADMA Biologics Inc's market cap, and TJX Companies Inc pays a 1.23% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMATJX
Market Cap
$2.22B$172.05B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$168.41
52-Week Low
$7.60$132.62
Enterprise Value
$2.29B$180.65B
Dividend Yield
1.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.

Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.

TJX Companies Inc

TJX trades at $152.64, down 3.88% in the last session, with a bearish technical signal but strong fundamentals including a 61.25% ROE and consistent earnings beats. Revenue grew to $56.36B in 2025, with net income margin expanding to 8.63%. The company maintains robust cash flow from operations at $6.12B and announced dividends of $0.48 per share for H1 and H2 2026.

Outlook remains positive with analyst consensus price target of $181.80 (19% upside), supported by 88% buy ratings. Risks include competitive discount retail pressures and macroeconomic sensitivity, but TJX's value proposition and growth trajectory offer investment opportunity pending Q2 2026 earnings on August 19, 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX